Literature DB >> 26715789

IV Administration of Erwinia-Derived Asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia: Single-Centre Case Series.

Denise Reniers1, Catherine Orr1, Paul Gibson2.   

Abstract

Entities:  

Year:  2015        PMID： 26715789      PMCID： PMC4690678          DOI： 10.4212/cjhp.v68i6.1507

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  13 in total

1.  High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase.

Authors:  Katja M J Heitink-Pollé; Berthil H C M T Prinsen; Tom J de Koning; Peter M van Hasselt; Marc B Bierings
Journal:  JIMD Rep       Date:  2012-07-01

2.  A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

Authors:  Wing H Tong; Rob Pieters; Gertjan J L Kaspers; D Maroeska W M te Loo; Marc B Bierings; Cor van den Bos; Wouter J W Kollen; Wim C J Hop; Claudia Lanvers-Kaminsky; Mary V Relling; Wim J E Tissing; Inge M van der Sluis
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

3.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Authors:  L B Silverman; R D Gelber; V K Dalton; B L Asselin; R D Barr; L A Clavell; C A Hurwitz; A Moghrabi; Y Samson; M A Schorin; S Arkin; L Declerck; H J Cohen; S E Sallan
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

Review 4.  Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients.

Authors:  L Lee Dupuis; Sabrina Boodhan; Lillian Sung; Carol Portwine; Richard Hain; Patricia McCarthy; Mark Holdsworth
Journal:  Pediatr Blood Cancer       Date:  2011-04-04       Impact factor: 3.167

5.  The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia.

Authors:  Beata Zalewska-Szewczyk; Witalij Andrzejewski; Wojciech Młynarski; Krystyna Jedrychowska-Dańska; Henryk Witas; Jerzy Bodalski
Journal:  Leuk Lymphoma       Date:  2007-05

Review 6.  Evidence-based recommendations for cancer nausea and vomiting.

Authors:  Arash Naeim; Sydney M Dy; Karl A Lorenz; Homayoon Sanati; Anne Walling; Steven M Asch
Journal:  J Clin Oncol       Date:  2008-08-10       Impact factor: 44.544

7.  Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.

Authors:  Lynda M Vrooman; Jeffrey G Supko; Donna S Neuberg; Barbara L Asselin; Uma H Athale; Luis Clavell; Kara M Kelly; Caroline Laverdière; Bruno Michon; Marshall Schorin; Harvey J Cohen; Stephen E Sallan; Lewis B Silverman
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

8.  Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients.

Authors:  L Lee Dupuis; Sabrina Boodhan; Mark Holdsworth; Paula D Robinson; Richard Hain; Carol Portwine; Erin O'Shaughnessy; Lillian Sung
Journal:  Pediatr Blood Cancer       Date:  2013-03-19       Impact factor: 3.167

Review 9.  Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.

Authors:  Augusto F Andrade; Kleiton S Borges; Vanessa S Silveira
Journal:  Clin Med Insights Oncol       Date:  2014-08-24

10.  Hyperammonemia secondary to asparaginase: A case series.

Authors:  Vicki Nussbaum; Nicole Lubcke; Russell Findlay
Journal:  J Oncol Pharm Pract       Date:  2014-09-22       Impact factor: 1.809
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.